Manipulating autophagic processes in autoimmune diseases: A special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Wang, Fengjuan ^a   Muller, Sylviane ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antigen MHCII presentation; Autoimmune diseases; Chaperone mediated autophagy; Lysosomal dysfunction; P140 peptide Lupuzor; Systemic lupus erythematosus

Indexed keywords

AMODIAQUINE; AZITHROMYCIN; CATHEPSIN K INHIBITOR; CATHEPSIN S INHIBITOR; CHAPERONE; CHLOROQUINE; FORIGERIMOD; GLUTAMATE DECARBOXYLASE; HYDROXYCHLOROQUINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; ODANACATIB; PHOSPHOPEPTIDE; PROTEINASE; RWJ 445380; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOPHAGY; CELL PH; CHAPERONE-MEDIATED AUTOPHAGY; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYSOSOME; LYSOSOME STORAGE DISEASE; MACROAUTOPHAGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROAUTOPHAGY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STARVATION; T LYMPHOCYTE;

EID: 84934294787     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00252     Document Type: Review

References (160)

1. Nakayama M. Antigen presentation by MHC-dressed cells. Front Immunol (2014) 5:672. doi:10.3389/fimmu.2014.00672
2. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A (2005) 102(22):7922-7. doi:10.1073/pnas.0501190102
3. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science (2005) 307(5709):593-6. doi:10.1126/science.1104904
4. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity (2005) 22(5):571-81. doi:10.1016/j.immuni.2005.03.009
5. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol (2008) 8(8):607-18. doi:10.1038/nri2368
6. Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 11(12):823-36. doi:10.1038/nri3084
7. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol (2013) 31:443-73. doi:10.1146/annurev-immunol-032712-095910
8. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest (2005) 115(7):1869-78. doi:10.1172/JCI23049
9. Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum (2011) 63(7):2058-66. doi:10.1002/art.30353
10. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol (2011) 7(1):9-17. doi:10.1038/nchembio.500
11. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature (2011) 469(7330):323-35. doi:10.1038/nature09782
12. Baek K-H, Park J, Shin I. Autophagy-regulating small molecules and their therapeutic applications. Chem Soc Rev (2012) 41(8):3245-63. doi:10.1039/C2CS15328A
13. Cheong H, Lu C, Lindsten T, Thompson CB. Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 30(7):671-8. doi:10.1038/nbt.2285
14. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov (2012) 11(9):709-30. doi:10.1038/nrd3802
15. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol (2014) 10(12):1013-9. doi:10.1038/nchembio.1681
16. Gros F, Muller S. Pharmacological regulators of autophagy and their link with modulators of lupus disease. Br J Pharmacol (2014) 171(19):4337-59. doi:10.1111/bph.12792
17. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, et al. Microautophagy of cytosolic proteins by late endosomes. Dev Cell (2011) 20(1):131-9. doi:10.1016/j.devcel.2010.12.003
18. Cuervo AM, Macian F. Autophagy and the immune function in aging. Curr Opin Immunol (2014) 29(0):97-104. doi:10.1016/j.coi.2014.05.006
19. Xie R, Nguyen S, McKeehan WL, Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol (2010) 11:89. doi:10.1186/1471-2121-11-89
20. Klionsky DJ, Codogno P. The mechanism and physiological function of macroautophagy. J Innate Immun (2013) 5(5):427-33. doi:10.1159/000351979
21. Hamasaki M, Shibutani ST, Yoshimori T. Up-to-date membrane biogenesis in the autophagosome formation. Curr Opin Cell Biol (2013) 25(4):455-60. doi:10.1016/j.ceb.2013.03.004
22. Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol (2014) 15(10):634-46. doi:10.1038/nrm3877
23. Brazil MI, Weiß S, Stockinger B. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules. Eur J Immunol (1997) 27(6):1506-14. doi:10.1002/eji.1830270629
24. Dörfel D, Appel S, Grünebach F, Weck MM, Müller MR, Heine A, et al. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood (2004) 105(8):3199-205. doi:10.1182/blood-2004-09-3556
25. Schmid D, Pypaert M, Münz C. MHC class II antigen loading compartments continuously receive input from autophagosomes. Immunity (2007) 26(1):79-92. doi:10.1016/j.immuni.2006.10.018
26. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, Chervonsky A, et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity (2010) 32(2):227-39. doi:10.1016/j.immuni.2009.12.006
27. Chiang HL, Dice JF. Peptide sequences that target proteins for enhanced degradation during serum withdrawal. J Biol Chem (1988) 263(14):6797-805.
28. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol (2012) 22(8):407-17. doi:10.1016/j.tcb.2012.05.006
29. Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res (2014) 24(1):92-104. doi:10.1038/cr.2013.153
30. Valdor R, Mocholi E, Botbol Y, Guerrero-Ros I, Chandra D, Koga H, et al. Chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation. Nat Immunol (2014) 15(11):1046-54. doi:10.1038/ni.3003
31. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev (2010) 90(4):1383-435. doi:10.1152/physrev.00030.2009
32. Li W, Yang Q, Mao Z. Chaperone-mediated autophagy: machinery, regulation and biological consequences. Cell Mol Life Sci (2011) 68(5):749-63. doi:10.1007/s00018-010-0565-6
33. Choi AMK, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med (2013) 368(7):651-62. doi:10.1056/NEJMra1205406
34. Jiang P, Mizushima N. Autophagy and human diseases. Cell Res (2014) 24(1):69-79. doi:10.1038/cr.2013.161
35. Deretic V. Autophagy as an immune defense mechanism. Curr Opin Immunol (2006) 18(4):375-82. doi:10.1016/j.coi.2006.05.019
36. Crotzer VL, Blum JS. Autophagy and its role in MHC-mediated antigen presentation. J Immunol (2009) 182(6):3335-41. doi:10.4049/jimmunol.0803458
37. Münz C. Antigen processing for MHC class II presentation via autophagy. Front Immunol (2012) 3:9. doi:10.3389/fimmu.2012.00009
38. Patterson N, Mintern J. Intersection of autophagy with pathways of antigen presentation. Protein Cell (2012) 3(12):911-20. doi:10.1007/s13238-012-2097-3
39. Gannage M, da Silva R, Münz C. Antigen processing for MHC presentation via macroautophagy. In: van Endert P, editor. Antigen Processing: Methods in Molecular Biology. (Vol. 960), New York, NY: Humana Press (2013). p. 473-88.
40. Romao S, Gannage M, Münz C. Checking the garbage bin for problems in the house, or how autophagy assists in antigen presentation to the immune system. Semin Cancer Biol (2013) 23(5):391-6. doi:10.1016/j.semcancer.2013.03.001
41. Bronietzki AW, Schuster M, Schmitz I. Autophagy in T-cell development, activation and differentiation. Immunol Cell Biol (2015) 93(1):25-34. doi:10.1038/icb.2014.81
42. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature (2008) 455(7211):396-400. doi:10.1038/nature07208
43. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med (2011) 208(13):2625-32. doi:10.1084/jem.20110640
44. Aichinger M, Wu C, Nedjic J, Klein L. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med (2013) 210(2):287-300. doi:10.1084/jem.20122149
45. Conway KL, Kuballa P, Khor B, Zhang M, Shi HN, Virgin HW, et al. ATG5 regulates plasma cell differentiation. Autophagy (2013) 9(4):528-37. doi:10.4161/auto.23484
46. Caza TN, Talaber G, Perl A. Metabolic regulation of organelle homeostasis in lupus T cells. Clin Immunol (2012) 144(3):200-13. doi:10.1016/j.clim.2012.07.001
47. Pierdominici M, Vomero M, Barbati C, Colasanti T, Maselli A, Vacirca D, et al. Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J (2012) 26(4):1400-12. doi:10.1096/fj.11-194175
48. Zhou X-J, Zhang H. Autophagy in immunity. Autophagy (2012) 8(9):1286-99. doi:10.4161/auto.21212
49. Jones SA, Mills KHG, Harris J. Autophagy and inflammatory diseases. Immunol Cell Biol (2013) 91(3):250-8. doi:10.1038/icb.2012.82
50. Gianchecchi E, Delfino DV, Fierabracci A. Recent insights on the putative role of autophagy in autoimmune diseases. Autoimmun Rev (2014) 13(3):231-41. doi:10.1016/j.autrev.2013.10.007
51. Zhou X-J, Cheng F-J, Zhang H. Emerging view of autophagy in systemic lupus erythematosus. Int Rev Immunol (2015) 34(3):280-92. doi:10.3109/08830185.2013.879711
52. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 40(2):204-10. doi:10.1038/ng.81
53. Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, et al. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (2011) 70(3):463-8. doi:10.1136/ard.2010.137174
54. Yang W, Tang H, Zhang Y, Tang X, Zhang J, Sun L, et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2013) 92(1):41-51. doi:10.1016/j.ajhg.2012.11.018
55. Majai G, Kiss E, Tarr T, Zahuczky G, Hartman Z, Szegedi G, et al. Decreased apopto-phagocytic gene expression in the macrophages of systemic lupus erythematosus patients. Lupus (2014) 23(2):133-45. doi:10.1177/0961203313511557
56. Ramos PS, Shaftman SR, Ward RC, Langefeld CD. Genes associated with SLE are targets of recent positive selection. Autoimmune Dis (2014) 2014:11. doi:10.1155/2014/203435
57. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2007) 39(2):207-11. doi:10.1038/ng1954
58. Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology (2011) 140(6):1738-47. doi:10.1053/j.gastro.2011.02.048
59. Henderson P, Stevens C. The role of autophagy in Crohn's disease. Cells (2012) 1(3):492-519. doi:10.3390/cells1030492
60. Lu XC, Tao Y, Wu C, Zhao PL, Li K, Zheng JY, et al. Association between variants of the autophagy related gene-IRGM and susceptibility to Crohn's disease and ulcerative colitis: a meta-analysis. PLoS One (2013) 8(11):e80602. doi:10.1371/journal.pone.0080602
61. Murthy A, Li Y, Peng I, Reichelt M, Katakam AK, Noubade R, et al. A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. Nature (2014) 506(7489):456-62. doi:10.1038/nature13044
62. Gros F, Arnold J, Page N, Décossas M, Korganow A-S, Martin T, et al. Macroautophagy is deregulated in murine and human lupus T lymphocytes. Autophagy (2012) 8(7):1113-23. doi:10.4161/auto.20275
63. Alessandri C, Barbati C, Vacirca D, Piscopo P, Confaloni A, Sanchez M, et al. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J (2012) 26(11):4722-32. doi:10.1096/fj.12-206060
64. Clarke AJ, Ellinghaus U, Cortini A, Stranks A, Simon AK, Botto M, et al. Autophagy is activated in systemic lupus erythematosus and required for plasmablast development. Ann Rheum Dis (2015) 74(5):912-20. doi:10.1136/annrheumdis-2013-204343
65. Li B, Yue Y, Dong C, Shi Y, Xiong S. Blockade of macrophage autophagy ameliorates activated lymphocytes-derived DNA induced murine lupus possibly via inhibition of proinflammatory cytokine production. Clin Exp Rheumatol (2014) 32(5):705-14.
66. Lin N-Y, Beyer C, Gießl A, Kireva T, Scholtysek C, Uderhardt S, et al. Autophagy regulates TNFa-mediated joint destruction in experimental arthritis. Ann Rheum Dis (2013) 72(5):761-8. doi:10.1136/annrheumdis-2012-201671
67. Kato M, Ospelt C, Gay RE, Gay S, Klein K. Dual role of autophagy in stress-induced cell death in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2014) 66(1):40-8. doi:10.1002/art.38190
68. Alirezaei M, Fox HS, Flynn CT, Moore CS, Hebb ALO, Frausto RF, et al. Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy (2009) 5(2):152-8. doi:10.4161/auto.5.2.7348
69. Xu X, Kobayashi S, Chen K, Timm D, Volden P, Huang Y, et al. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J Biol Chem (2013) 288(25):18077-92. doi:10.1074/jbc. M113.474650
70. Yamahara K, Yasuda M, Kume S, Koya D, Maegawa H, Uzu T. The role of autophagy in the pathogenesis of diabetic nephropathy. J Diabetes Res (2013) 2013:193757. doi:10.1155/2013/193757
71. Wilhelm M, Muller S. Target autophagy as a novel therapeutic strategy in inflammation-based pathologies. Autophagy Networks in Inflammation. Springer Publishing Company (2015).
72. Theofilopoulos NA, Dixon JF. Murine models of systemic lupus erythematosus. Adv Immunol (1985) 37:122.
73. Perry D, Sang A, Yin Y, Zheng Y-Y, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol (2011) 2011:271694. doi:10.1155/2011/271694
74. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med (1992) 176(6):1645-56. doi:10.1084/jem.176.6.1645
75. Page N, Gros F, Schall N, Décossas M, Bagnard D, Briand J-P, et al. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis (2011) 70(5):837-43. doi:10.1136/ard.2010.139832
76. Macri C, Wang F, Tasset I, Schall N, Page N, Briand J-P, et al. Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide. Autophagy (2015) 11(3):472-86. doi:10.1080/15548627.2015.1017179
77. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci U S A (2006) 103(15):5805-10. doi:10.1073/pnas.0507436103
78. Kaushik S, Massey AC, Mizushima N, Cuervo AM. Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. Mol Biol Cell (2008) 19(5):2179-92. doi:10.1091/mbc. E07-11-1155
79. Wu H, Chen S, Ammar A-B, Xu J, Wu Q, Pan K, et al. Crosstalk between macroautophagy and chaperone-mediated autophagy: implications for the treatment of neurological diseases. Mol Neurobiol (2014):1-13. doi:10.1007/s12035-014-8933-0
80. Kobayashi T, Tanaka T, Toyama-Sorimachi N. How do cells optimize luminal environments of endosomes/lysosomes for efficient inflammatory responses? J Biochem (2013) 154(6):491-9. doi:10.1093/jb/mvt099
81. Ge W, Li D, Gao Y, Cao X. The roles of lysosomes in inflammation and autoimmune diseases. Int Rev Immunol (2014). doi:10.3109/08830185.2014.936587
82. Ghislat G, Knecht E. Ca2+-sensor proteins in the autophagic and endocytic traffic. Curr Protein Pept Sci (2013) 14(2):97-110. doi:10.2174/13892037112139990033
83. Weissmann G, Thomas L. Steroids, lysosomes and systemic lupus erythematosus. Bull N Y Acad Med (1962) 38(12):779-87.
84. Kallenberg CG, Cohen Tervaert JW, van der Woude FJ, Goldschmeding R, von dem Borne AE, Weening JJ. Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? Immunol Today (1991) 12(2):61-4. doi:10.1016/0167-5699(91)90159-Q
85. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol (2003) 3(6):472-82. doi:10.1038/nri1110
86. Chapman HA. Endosomal proteases in antigen presentation. Curr Opin Immunol (2006) 18(1):78-84. doi:10.1016/j.coi.2005.11.011
87. Bird PI, Trapani JA, Villadangos JA. Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol (2009) 9(12):871-82. doi:10.1038/nri2671
88. van Kasteren SI, Overkleeft HS. Endo-lysosomal proteases in antigen presentation. Curr Opin Chem Biol (2014) 23(0):8-15. doi:10.1016/j.cbpa.2014.08.011
89. Manoury B. Proteases: essential actors in processing antigens and intracellular toll-like receptors. Front Immunol (2013) 4:299. doi:10.3389/fimmu.2013.00299
90. Riese RJ, Wolf PR, Brömme D, Natkin LR, Villadangos JA, Ploegh HL, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity (1996) 4(4):357-66. doi:10.1016/S1074-7613(00)80249-6
91. Costantino CM, Ploegh HL, Hafler DA. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells. J Immunol (2009) 183(2):945-52. doi:10.4049/jimmunol.0900921
92. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science (1998) 280(5362):450-3. doi:10.1126/science.280.5362.450
93. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest (2003) 112(4):517-26. doi:10.1172/JCI200318028
94. Shi G-P, Bryant RAR, Riese R, Verhelst S, Driessen C, Li Z, et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med (2000) 191(7):1177-86. doi:10.1084/jem.191.7.1177
95. Vidard L, Rock KL, Benacerraf B. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J Immunol (1991) 147(6):1786-91.
96. Watts C, Moss CX, Mazzeo D, West MA, Matthews SP, Li DN, et al. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann N Y Acad Sci (2003) 987(1):9-14. doi:10.1111/j.1749-6632.2003.tb06028.x
97. Manoury-Schwartz B, Chiocchia G, Lotteau V, Fournier C. Selective increased presentation of type II collagen by leupeptin. Int Immunol (1997) 9(4):581-9. doi:10.1093/intimm/9.4.581
98. Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity (2000) 12(3):233-9. doi:10.1016/S1074-7613(00)80176-4
99. Otomo T, Schweizer M, Kollmann K, Schumacher V, Muschol N, Tolosa E, et al. Mannose 6 phosphorylation of lysosomal enzymes controls B cell functions. J Cell Biol (2015) 208(2):171-80. doi:10.1083/jcb.201407077
100. Watts C, Matthews SP, Mazzeo D, Manoury B, Moss CX. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol Rev (2005) 207(1):218-28. doi:10.1111/j.0105-2896.2005.00312.x
101. Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med (2006) 203(9):2049-55. doi:10.1084/jem.20052442
102. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 307(5715):1630-4. doi:10.1126/science.1108003
103. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol (2002) 3(2):169-74. doi:10.1038/ni754
104. Moss CX, Villadangos JA, Watts C. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing. Eur J Immunol (2005) 35(12):3442-51. doi:10.1002/eji.200535320
105. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med (2011) 208(4):643-51. doi:10.1084/jem.20100682
106. Toscano F, Estornes Y, Virard F, Garcia-Cattaneo A, Pierrot A, Vanbervliet B, et al. Cleaved/associated TLR3 represents the primary form of the signaling receptor. J Immunol (2013) 190(2):764-73. doi:10.4049/jimmunol.1202173
107. Qi R, Singh D, Kao CC. Proteolytic processing regulates toll-like receptor 3 stability and endosomal localization. J Biol Chem (2012) 287(39):32617-29. doi:10.1074/jbc. M112.387803
108. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E, et al. Critical role for asparagine endopeptidase in endocytic toll-like receptor signaling in dendritic cells. Immunity (2009) 31(5):737-48. doi:10.1016/j.immuni.2009.09.013
109. Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh H-J, Jeong JU, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem (2006) 49(5):1597-612. doi:10.1021/jm050915u
110. Li X, Wu K, Edman M, Schenke-Layland K, MacVeigh-Aloni M, Janga SR, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci (2010) 51(10):5019-29. doi:10.1167/iovs.09-4523
111. Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, et al. Tear cathepsin S as a candidate biomarker for Sjögren's syndrome. Arthritis Rheum (2014) 66(7):1872-81. doi:10.1002/art.38633
112. Phi N, Chien D, Binh V, Gergely O. Cathepsin d-like activity in serum of patients with systemic lupus erythematosus. J Clin Lab Immunol (1989) 29(4):4.
113. Valli Rupanagudi K, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis (2015) 74(2):452-63. doi:10.1136/annrheumdis-2013-203717
114. Nishi T, Forgac M. The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol (2002) 3(2):94-103. doi:10.1038/nrm729
115. Mindell JA. Lysosomal acidification mechanisms. Annu Rev Physiol (2012) 74(1):69-86. doi:10.1146/annurev-physiol-012110-142317
116. Wolfe DM, Lee J-H, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci (2013) 37(12):1949-61. doi:10.1111/ejn.12169
117. Guha S, Coffey EE, Lu W, Lim JC, Beckel JM, Laties AM, et al. Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations. Exp Eye Res (2014) 126(0):68-76. doi:10.1016/j.exer.2014.05.013
118. Diwu Z, Chen C-S, Zhang C, Klaubert DH, Haugland RP. A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Chem Biol (1999) 6(7):411-8. doi:10.1016/S1074-5521(99)80059-3
119. Suh C-H, Freed JH, Cohen PL. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice. J Immunol (2003) 170(4):2229-35. doi:10.4049/jimmunol.170.4.2229
120. Cho K, Seki S, Nakatani K, Kobayashi K, Kaneda K. Kupffer cell activation and hematopoiesis in the liver of autoimmune MRL-lpr/lpr mice. Arch Histol Cytol (2000) 63(5):473-83. doi:10.1679/aohc.63.473
121. Castaneda J, Lim M, Cooper J, Pearce D. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol (2008) 115(2):159-74. doi:10.1007/s00401-007-0296-4
122. Sandri M, Coletto L, Grumati P, Bonaldo P. Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies. J Cell Sci (2013) 126(23):5325-33. doi:10.1242/jcs.114041
123. Killedar S, DiRosario J, Divers E, Popovich P, McCarty D, Fu H. Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J Neuroinflammation (2010) 7(1):39. doi:10.1186/1742-2094-7-39
124. Wang JY, Roehrl MH. Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proc Natl Acad Sci U S A (2002) 99(22):14362-7. doi:10.1073/pnas.222536599
125. Dimitriu-Bona A, Fillit H. Studies of the cellular immune response to heparan sulfate proteoglycan in the tight skin mouse. Cell Immunol (1993) 150(2):321-32. doi:10.1006/cimm.1993.1200
126. Dimitriu-Bona A, Matic M, Ding W, Yang CP, Fillit H. Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. Clin Immunol Immunopathol (1995) 76:234-40. doi:10.1006/clin.1995.1121
127. Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A. Autophagy in lysosomal storage disorders. Autophagy (2012) 8(5):719-30. doi:10.4161/auto.19469
128. Elrick MJ, Lieberman AP. Autophagic dysfunction in a lysosomal storage disorder due to impaired proteolysis. Autophagy (2013) 9(2):234-5. doi:10.4161/auto.22501
129. Nelson MP, Tse TE, O'Quinn DB, Percival SM, Jaimes EA, Warnock DG, et al. Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Acta Neuropathol Commun (2014) 2:20. doi:10.1186/2051-5960-2-20
130. Schneider JL, Cuervo AM. Autophagy and human disease: emerging themes. Curr Opin Genet Dev (2014) 26(0):16-23. doi:10.1016/j.gde.2014.04.003
131. Pierdominici M, Barbati C, Vomero M, Locatelli SL, Carlo-Stella C, Ortona E, et al. Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders. FASEB J (2014) 28(2):524-35. doi:10.1096/fj.13-235655
132. Alvarado R, O'Brien B, Tanaka A, Dalton JP, Donnelly S. A parasitic helminth-derived peptide that targets the macrophage lysosome is a novel therapeutic option for autoimmune disease. Immunobiology (2015) 220(2):262-9. doi:10.1016/j.imbio.2014.11.008
133. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A (1982) 79(1):175-8. doi:10.1073/pnas.79.1.175
134. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum (1993) 23(2, Suppl 1):82-91. doi:10.1016/S0049-0172(10)80012-5
135. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis (2010) 69(01):20-8. doi:10.1136/ard.2008.101766
136. Costedoat-Chalumeau N, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study). Ann Rheum Dis (2013) 72(11):1786-92. doi:10.1136/annrheumdis-2012-202322
137. Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev (2015) 14(4):358-62. doi:10.1016/j.autrev.2014.12.006
138. Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren's syndrome: the joquer randomized clinical trial. JAMA (2014) 312(3):249-58. doi:10.1001/jama.2014.7682
139. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells GA, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev (2000) 4:CD000959. doi:10.1002/14651858.CD000959
140. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 73(3):529-35. doi:10.1136/annrheumdis-2013-204575
141. Thomé R, Issayama LK, DiGangi R, Bombeiro AL, da Costa TA, Ferreira IT, et al. Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. Immunol Cell Biol (2014) 92(2):124-32. doi:10.1038/icb.2013.73
142. Thomé R, Lopes SCP, Costa FTM, Verinaud L. Chloroquine: modes of action of an undervalued drug. Immunol Lett (2013) 153(1-2):50-7. doi:10.1016/j.imlet.2013.07.004
143. Phillips BN, Chun DW. Hydroxychloroquine retinopathy after short-term therapy. Retin Cases Brief Rep (2014) 8(1):67-9. doi:10.1097/ICB.0000000000000006
144. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest (2011) 121(9):3554-63. doi:10.1172/JCI46095
145. Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat (2011) 21(3):311-37. doi:10.1517/13543776.2011.553800
146. Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest (2002) 110(3):361-9. doi:10.1172/JCI14682
147. Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, et al. Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds. J Med Chem (2013) 56(23):9789-801. doi:10.1021/jm401528k
148. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 25(5):937-47. doi:10.1359/jbmr.091035
149. Toomey CB, Cauvi DM, Hamel JC, Ramirez AE, Pollard KM. Cathepsin B regulates the appearance and severity of mercury-induced inflammation and autoimmunity. Toxicol Sci (2014) 142(2):339-49. doi:10.1093/toxsci/kfu189
150. Vidal RL, Matus S, Bargsted L, Hetz C. Targeting autophagy in neurodegenerative diseases. Trends Pharmacol Sci (2014) 35(11):583-91. doi:10.1016/j.tips.2014.09.002
151. Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nat Chem Biol (2013) 9(6):374-82. doi:10.1038/nchembio.1230
152. Fan X, Jin WY, Lu J, Wang J, Wang YT. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci (2014) 17(3):471-80. doi:10.1038/nn.3637
153. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. Autophagy (2005) 1(3):141-5. doi:10.4161/auto.1.3.2000
154. Page N, Schall N, Strub J-M, Quinternet M, Chaloin O, Décossas M, et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδd T cells. PLoS One (2009) 4(4):e5273. doi:10.1371/journal.pone.0005273
155. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis (2013) 72(11):1830-5. doi:10.1136/annrheumdis-2012-202460
156. Monneaux F, Lozano JM, Patarroyo ME, Briand J-P, Muller S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice. Eur J Immunol (2003) 33(2):287-96. doi:10.1002/immu.200310002
157. Schall N, Page N, Macri C, Chaloin O, Briand J-P, Muller S. Peptide-based approaches to treat lupus and other autoimmune diseases. J Autoimmun (2012) 39(3):143-53. doi:10.1016/j.jaut.2012.05.016
158. Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, Wiesel P, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum (2008) 58(12):3873-83. doi:10.1002/art.24027
159. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol (2008) 28(18):5747-63. doi:10.1128/MCB.02070-07
160. Monneaux F, Parietti V, Briand J-P, Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther (2007) 9(5):R111. doi:10.1186/ar2317